|1.||Dranoff, Glenn: 31 articles (07/2015 - 02/2002)|
|2.||Trapnell, Bruce C: 27 articles (11/2014 - 01/2002)|
|3.||Nakata, Koh: 24 articles (01/2015 - 02/2004)|
|4.||Hodi, F Stephen: 19 articles (12/2015 - 05/2002)|
|5.||Jaffee, Elizabeth M: 18 articles (04/2015 - 08/2003)|
|6.||Thomassen, Mary Jane: 18 articles (01/2013 - 10/2002)|
|7.||Hamilton, John A: 17 articles (09/2015 - 08/2002)|
|8.||Jooss, Karin: 17 articles (01/2014 - 03/2005)|
|9.||Kavuru, Mani S: 17 articles (01/2013 - 04/2002)|
|10.||Tazawa, Ryushi: 14 articles (04/2014 - 05/2005)|
11/15/2004 - "In conclusion, vaccinations with dendritic cells associated with apoptotic tumor cells secreting GM-CSF show a very high therapeutic potency that should show promise for the treatment of human cancer."
03/18/2003 - "Vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor generates potent, specific, and long-lasting antitumor immunity through improved tumor antigen presentation by dendritic cells and macrophages. "
01/01/2000 - "After complete tumor eradication, those mice treated with DC-AdIL-7 evidenced significantly greater release of splenocyte GM-CSF and IFN-gamma than did controls or AdIL-7-treated mice. "
07/01/1997 - "All immune parameters were significantly improved during treatment in Group 1 but remained unchanged or even deteriorated in Group 2. Administration of GM-CSF during treatment of cancer patients with conventional chemotherapeutic drugs results in a marked potentiation of deficient cellular immune responses in vitro and a change towards normalisation of cytokine serum levels. "
08/21/2013 - "Injection of the recombinant mouse HSV encoding GM-CSF resulted in a significant reduction in tumor growth compared to the control group, and dose-dependent effects were observed: the relative tumor proliferation rates of the low dose, medium dose and high dose groups on 15 d after injection were 45.5%, 55.2% and 65.5%, respectively. "
09/01/1991 - "Under GM-CSF the blood neutrophils recovered 6 and 9 days earlier in the TAD9 (P = .009) and S-HAM (P = .043) groups associated with a rapid clearance of infections in most patients. "
08/01/2005 - "GM-CSF, in addition to IS, may shorten time to neutrophil count recovery, may be beneficial in decreasing infection rates, and may improve platelet response in patients with SAA. "
03/01/2000 - "Lung GM-CSF levels increased progressively during the infection and were significantly greater than those in uninfected controls 3, 4, and 5 wk after inoculation. "
01/01/2000 - "By use of a flow cytometric assay to quantify phagocytosis, HIV-1 infection was found to impair the ability of monocyte-derived macrophages to phagocytose MAC in vitro, whereas GM-CSF significantly improved this defect. "
01/01/2014 - "Our results indicated that the expression of GM-CSF during infection with a vaccine strain could enhance the activation of BMDCs and increase cytokine response, which is expected to result in higher immune responses and may improve vaccine efficacy against PRRSV infection."
05/01/1989 - "In conclusion, GM-CSF is well tolerated by the SC route and induces striking, but usually temporary, improvement in the neutropenia of MDS. "
06/22/1995 - "The median duration of neutropenia was slightly shorter (P = 0.02) in the patients who received GM-CSF (15 days) than in those who received placebo (17 days), but the clinical importance of this result was minimal because the growth factor failed to lower the treatment-related mortality rate or improve the rate of complete remission. "
07/01/2001 - "In this series, GM-CSF was shown to be effective on iatrogenic neutropenia and related complications, with no impact on thrombopoiesis, drug dose escalation and outcome."
12/01/1998 - "We conclude that GM-CSF is effective in improving CLL associated chronic neutropenia and also enhances impaired granulocyte chemiluminescence. "
09/01/1994 - "Neutropenia induced by antiviral treatment, in particular AZT, can be improved with recombinant human granulocyte macrophage colony stimulating factor (RHGMCSF) in HIV positive patients. "
|4.||Melanoma (Melanoma, Malignant)
06/15/1993 - "Treatment with GM-CSF alone or with antibody alone had no effect, whereas therapy with combination of both these agents resulted in a significant reduction in dissemination of melanoma both in a nontransplant as well as in BMT settings, with results being more optimal in the latter setting. "
12/01/2015 - "Neither adjuvant GM-CSF nor PV significantly improved RFS or OS in patients with high-risk resected melanoma. "
04/01/2000 - "GM-CSF may provide an antitumor effect that prolongs survival and disease-free survival in patients with stage III and IV melanoma who are clinically disease-free. "
03/01/2015 - "A variety of viruses are now in clinical development with the attenuated oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor, known as talimogene laherparepvec, recently demonstrating an improvement in durable response rate in patients with advanced melanoma compared with granulocyte-macrophage colony stimulating factor alone. "
12/01/2015 - "In a randomized phase III trial, T-VEC met its primary endpoint of improving the durable response rate vs granulocyte-macrophage colony-stimulating factor in patients with unresectable melanoma. "
|5.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/01/2007 - "To observe the therapeutic efficacy of 131I-labeled granulocyte macrophage colony-stimulating factor (GM-SCF) in SCID mouse-acute myeloid leukemia model, and the relationship between dose and effect. "
04/01/1998 - "Granulocyte-macrophage colony-stimulating factor in post-remission therapy of acute myeloid leukemia."
07/01/2013 - "The objective of this study was to generate a novel humanized chimeric protein with human DFF40 fused with GM-CSF for targeting acute myeloid leukemia (AML) cells. "
01/01/2007 - "[Experimental study of 131I-labeled granulocyte macrophage colony-stimulating factor in SCID mouse-acute myeloid leukemia model]."
01/15/2004 - "A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group."
|1.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|2.||Granulocyte Colony-Stimulating Factor (G-CSF)
|5.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|7.||Interleukin-12 (IL 12)
|8.||Interleukin-3 (Interleukin 3)
|1.||Drug Therapy (Chemotherapy)
|4.||Bone Marrow Transplantation (Transplantation, Bone Marrow)